Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up—a large series of all-comers

References

• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71–86
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Schror K, Weisman S, Fitzgerald GA. Terms and Conditions: Semantic complexity and aspirin resistance. Circulation. 2004; 110: 1706–8
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004; 24: 1–8
   Google Scholar
• Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003; 41: 961–5
   PubMed Web of Science ®Google Scholar
• Pamukcu B, Oflaz H, Oncul A, Umman B, Mercanoglu F, Ozcan M, et al. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis. 2006; 22: 103–10
   PubMed Web of Science ®Google Scholar
• Hobikoglu GF, Norgaz T, Aksu H, Ozer O, Erturk M, Destegul E, et al. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol. 2007; 23: 201–6
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Chloravicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502
   PubMed Web of Science ®Google Scholar
• Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Saleim D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999; 100: 593–601
   Google Scholar
• Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. Pursuit Investigators. Am J Cardiol. 1999; 83: 1147–51
   PubMed Web of Science ®Google Scholar
• Lancaster GI, Lancaster CJ, Radley D, Cohen M. Prior aspirin use in unstable angina predisposes to higher risk: the aspirin paradox. Int J Cardiol. 2001; 80: 201–7
   Google Scholar
• Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004; 110: 2361–7
   PubMed Web of Science ®Google Scholar
• Nikus KC, Eskola MJ, Virtanen VK, Harju J, Huhtala H, Mikkelsson J, et al. Mortality of patients with acute coronary syndrome still remains high: a follow-up study of 1188 consecutive patients admitted to a university hospital. Ann Med. 2007; 39: 63–71
   PubMed Web of Science ®Google Scholar
• Cohen M, Adams PC, McBride R, Blanke H, Fuster V. Prospective comparison of patient characteristics and outcome of non-prior aspirin users versus aspirin users with unstable angina or non-Q-wave myocardial infarction treated with combination antithrombotic therapy. J Thromb Thrombolysis. 1997; 4: 275–80
   Google Scholar
• Portnay EL, Foody JM, Rathore SS, Wang Y, Masoudi FA, Curtis JP, et al. Prior aspirin use and outcomes in elderly patients hospitalized for acute myocardial infarction. J Am Coll Cardiol. 2005; 46: 967–74
   Google Scholar
• Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost. 2004; 92: 1175–81
   PubMed Web of Science ®Google Scholar
• Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, et al. Cyclo-oxygenase 1 haplotype modulates platelet response to aspirin. J Thromb Haemost. 2005; 3: 2340–5
   PubMed Web of Science ®Google Scholar
• Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost. 2006; 95: 253–9
   PubMed Web of Science ®Google Scholar
• Kottke-Marchant K, Murugesan G, Gerber C, Chisolm GM, Moliterno DJ, Topol EJ, , et al. High prevalence of aspirin resistance in patients with a history of myocardial infarction. J Thromb Haemostasis 2003;1 (Suppl 1),OC243.
   Google Scholar
• Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, et al. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004; 43: 972–8
   PubMedGoogle Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358: 527–33
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, Delago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomised controlled trial. JAMA. 2002; 288: 2411–20
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 42,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366: 1607–21
   PubMed Web of Science ®Google Scholar
• Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002; 347: 969–74
   PubMed Web of Science ®Google Scholar
• Van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002; 360: 109–13
   PubMed Web of Science ®Google Scholar
• Kennon S, Barakat K, Suliman A, MacCallum PK, Ranjadayalan K, Wilkinson P, et al. Influence of previous aspirin treatment and smoking on the electrocardiographic manifestations of injury in acute myocardial infarction. Heart. 2000; 84: 41–5
   Google Scholar
• Bjorklund E, Lindahl B, Stenestrand U, Swahn E, Dellborg M, Pehrsson K, et al. Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. Am Heart J. 2004; 148: 566–73
   PubMed Web of Science ®Google Scholar
• Terkelsen CJ, Lassen JF, Norgaard BL, Gerdes JC, Jensen T, Gotzsche LB, et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. Eur Heart J. 2005; 26: 18–26
   PubMed Web of Science ®Google Scholar
• Mehta RH, Roe MT, Chen AY, Lytle BL, Pollack CV, Jr, Brindis RG, et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med. 2006; 166: 2027–34
   PubMed Web of Science ®Google Scholar